Citigroup
TEVA icon

Citigroup’s Teva Pharmaceuticals TEVA Stock Holding History

Citigroup’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-178,300
Closed -$5.56M – 6392
2025
Q4 		$5.56M Sell
178,300
-2,358,600
-93% -$58.1M ﹤0.01% 1944
2025
Q3 		$51.2M Buy
2,536,900
+2,410,900
+1,913% +$42.3M 0.02% 623
2025
Q2 		$2.11M Sell
126,000
-5,874,000
-98% -$94.8M ﹤0.01% 2597
2025
Q1 		$92.2M Buy
6,000,000
+5,072,700
+547% +$90.6M 0.05% 344
2024
Q4 		$20.4M Sell
927,300
-1,422,700
-61% -$25.9M 0.01% 948
2024
Q3 		$42.3M Hold
2,350,000
– – 0.02% 607
2024
Q2 		$38.2M Sell
2,350,000
-3,875,000
-62% -$59.7M 0.02% 606
2024
Q1 		$87.8M Buy
6,225,000
+5,735,000
+1,170% +$72.3M 0.06% 306
2023
Q4 		$5.12M Sell
490,000
-1,306,600
-73% -$12.2M ﹤0.01% 1577
2023
Q3 		$18.3M Sell
1,796,600
-500,000
-22% -$4.66M 0.01% 805
2023
Q2 		$17.3M Sell
2,296,600
-9,391,200
-80% -$76.2M 0.01% 896
2023
Q1 		$103M Buy
11,687,800
+3,029,000
+35% +$29.9M 0.07% 217
2022
Q4 		$79M Buy
8,658,800
+1,456,600
+20% +$12.7M 0.06% 280
2022
Q3 		$58.1M Sell
7,202,200
-700,000
-9% -$6.19M 0.04% 339
2022
Q2 		$59.4M Sell
7,902,200
-292,800
-4% -$2.55M 0.04% 339
2022
Q1 		$77M Sell
8,195,000
-3,279,000
-29% -$27.4M 0.05% 345
2021
Q4 		$91.9M Buy
11,474,000
+9,734,700
+560% +$87.9M 0.05% 345
2021
Q3 		$16.9M Sell
1,739,300
-250,000
-13% -$2.34M 0.01% 1096
2021
Q2 		$19.7M Sell
1,989,300
-1,789,800
-47% -$18.9M 0.01% 1009
2021
Q1 		$43.6M Buy
3,779,100
+814,100
+27% +$9.34M 0.03% 550
2020
Q4 		$28.6M Sell
2,965,000
-2,183,900
-42% -$20.9M 0.02% 824
2020
Q3 		$46.4M Buy
5,148,900
+1,327,400
+35% +$14M 0.03% 483
2020
Q2 		$47.1M Sell
3,821,500
-885,900
-19% -$10M 0.04% 412
2020
Q1 		$42.3M Buy
4,707,400
+739,400
+19% +$7.58M 0.04% 419
2019
Q4 		$38.9M Buy
3,968,000
+66,500
+2% +$594K 0.03% 616
2019
Q3 		$26.8M Buy
3,901,500
+2,535,900
+186% +$19.4M 0.02% 763
2019
Q2 		$12.6M Buy
1,365,600
+127,900
+10% +$1.54M 0.01% 1233
2019
Q1 		$19.4M Sell
1,237,700
-62,400
-5% -$1.1M 0.02% 846
2018
Q4 		$20M Buy
1,300,100
+64,300
+5% +$1.32M 0.02% 827
2018
Q3 		$26.6M Buy
1,235,800
+410,100
+50% +$9.52M 0.02% 676
2018
Q2 		$20.1M Sell
825,700
-421,600
-34% -$8.6M 0.02% 809
2018
Q1 		$21.3M Sell
1,247,300
-145,200
-10% -$2.84M 0.02% 746
2017
Q4 		$26.4M Buy
1,392,500
+587,400
+73% +$8.84M 0.02% 703
2017
Q3 		$14.2M Buy
805,100
+237,300
+42% +$5.34M 0.01% 1002
2017
Q2 		$18.9M Buy
567,800
+55,800
+11% +$1.73M 0.02% 787
2017
Q1 		$16.4M Sell
512,000
-656,900
-56% -$22.4M 0.01% 840
2016
Q4 		$42.4M Buy
1,168,900
+110,500
+10% +$4.41M 0.04% 430
2016
Q3 		$48.7M Buy
1,058,400
+59,500
+6% +$3.1M 0.05% 349
2016
Q2 		$50.2M Buy
998,900
+738,100
+283% +$39.3M 0.05% 323
2016
Q1 		$14M Sell
260,800
-599,600
-70% -$35.2M 0.02% 791
2015
Q4 		$56.5M Buy
860,400
+171,400
+25% +$10.6M 0.06% 327
2015
Q3 		$38.9M Sell
689,000
-56,500
-8% -$3.66M 0.04% 423
2015
Q2 		$44.1M Buy
745,500
+180,500
+32% +$11.1M 0.04% 431
2015
Q1 		$35.2M Sell
565,000
-270,300
-32% -$15.7M 0.03% 489
2014
Q4 		$48M Sell
835,300
-74,800
-8% -$4.17M 0.04% 417
2014
Q3 		$48.9M Buy
910,100
+403,100
+80% +$21.4M 0.04% 400
2014
Q2 		$26.6M Sell
507,000
-563,600
-53% -$28.8M 0.03% 635
2014
Q1 		$56.6M Buy
1,070,600
+173,800
+19% +$8.03M 0.06% 283
2013
Q4 		$35.9M Buy
896,800
+778,200
+656% +$30.6M 0.03% 499
2013
Q3 		$4.48M Sell
118,600
-11,500
-9% -$449K ﹤0.01% 1845
2013
Q2 		$5.1M Buy
+130,100
New +$5.07M 0.01% 1609

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's TEVA Position: Q1 2026 in Review

Citigroup reduced its Teva Pharmaceuticals (TEVA) stake by 38% in Q1 2026, selling an estimated $16.4M and leaving 832,323 shares worth $25.1M. The position accounts for 0.01% of the portfolio, ranked #953.

Citigroup first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $135M in Q2 2018. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Citigroup held 832,323 shares of Teva Pharmaceuticals worth $25.1M as of Q1 2026.
  • Citigroup sold 511,168 Teva Pharmaceuticals shares in Q1 2026, an estimated $16.4M.
  • Teva Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #953 holding.
  • Citigroup first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Teva Pharmaceuticals position peaked at $135M in Q2 2018.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.